Enanta Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
- Conditions
- RSV InfectionDrug Drug Interaction
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06917508
- Locations
- πΊπΈ
ICON, plc, San Antonio, Texas, United States
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- Conditions
- RSV InfectionDrug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06847464
- Locations
- πΊπΈ
ICON, plc, San Antonio, Texas, United States
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
- Conditions
- RSV InfectionQTc Interval
- Interventions
- Drug: zelicapavir (therapeutic dose)Drug: zelicapavir (supratherapeutic dose)Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT06601192
- Locations
- πΊπΈ
ICON Early Phase, LLC, San Antonio, Texas, United States
πΊπΈICON, Lenexa, Kansas, United States
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
- Conditions
- RSV Infection
- Interventions
- Drug: EDP-323 Dose Regimen 1Drug: EDP-323 Dose Regimen 2Drug: Placebo
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 142
- Registration Number
- NCT06170242
- Locations
- π¬π§
hVIVO Services Limited, London, United Kingdom
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 231
- Registration Number
- NCT05616728
- Locations
- πΊπΈ
Torrance Clinical Research Institute, Lomita, California, United States
πΊπΈLA Universal Research Center, Inc., Los Angeles, California, United States
πΊπΈMedBio Trials - Miami, Aventura, Florida, United States
Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT05594615
- Locations
- πΊπΈ
ICON, plc., Salt Lake City, Utah, United States
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05594602
- Locations
- πΊπΈ
ICON, plc., Lenexa, Kansas, United States
A Study of EDP-323 in Healthy Subjects
- First Posted Date
- 2022-10-20
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 82
- Registration Number
- NCT05587478
- Locations
- πΊπΈ
ICON, plc., Lenexa, Kansas, United States
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 186
- Registration Number
- NCT05568706
- Locations
- πΊπΈ
Longwood Research, Huntsville, Alabama, United States
πΊπΈVoyage Medical, Tempe, Arizona, United States
πΊπΈVoyage Medical, Tempe, Arizona, United States
A Study of EDP-235 in Healthy Subjects
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT05246878
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States